1. Home
  2. VRTX vs CMCSA Comparison

VRTX vs CMCSA Comparison

Compare VRTX & CMCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • CMCSA
  • Stock Information
  • Founded
  • VRTX 1989
  • CMCSA 1963
  • Country
  • VRTX United States
  • CMCSA United States
  • Employees
  • VRTX N/A
  • CMCSA N/A
  • Industry
  • VRTX EDP Services
  • CMCSA Cable & Other Pay Television Services
  • Sector
  • VRTX Technology
  • CMCSA Telecommunications
  • Exchange
  • VRTX Nasdaq
  • CMCSA Nasdaq
  • Market Cap
  • VRTX 115.6B
  • CMCSA 129.2B
  • IPO Year
  • VRTX 1991
  • CMCSA 1972
  • Fundamental
  • Price
  • VRTX $445.37
  • CMCSA $35.31
  • Analyst Decision
  • VRTX Buy
  • CMCSA Buy
  • Analyst Count
  • VRTX 26
  • CMCSA 22
  • Target Price
  • VRTX $510.48
  • CMCSA $43.16
  • AVG Volume (30 Days)
  • VRTX 1.3M
  • CMCSA 20.2M
  • Earning Date
  • VRTX 07-31-2025
  • CMCSA 07-31-2025
  • Dividend Yield
  • VRTX N/A
  • CMCSA 3.69%
  • EPS Growth
  • VRTX N/A
  • CMCSA 7.84
  • EPS
  • VRTX N/A
  • CMCSA 4.07
  • Revenue
  • VRTX $11,099,700,000.00
  • CMCSA $123,560,000,000.00
  • Revenue This Year
  • VRTX $10.48
  • CMCSA $1.89
  • Revenue Next Year
  • VRTX $10.69
  • CMCSA $2.98
  • P/E Ratio
  • VRTX N/A
  • CMCSA $8.79
  • Revenue Growth
  • VRTX 8.98
  • CMCSA 1.33
  • 52 Week Low
  • VRTX $377.85
  • CMCSA $31.44
  • 52 Week High
  • VRTX $519.88
  • CMCSA $45.31
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 45.87
  • CMCSA 54.64
  • Support Level
  • VRTX $436.81
  • CMCSA $34.16
  • Resistance Level
  • VRTX $451.88
  • CMCSA $35.28
  • Average True Range (ATR)
  • VRTX 9.25
  • CMCSA 0.54
  • MACD
  • VRTX 0.32
  • CMCSA 0.02
  • Stochastic Oscillator
  • VRTX 28.02
  • CMCSA 65.22

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About CMCSA Comcast Corporation

Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to 64 million US homes and businesses, or nearly half of the country. About 50% of the locations in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC network, the Peacock streaming platform, several local NBC affiliates, Universal Studios, and several theme parks. The firm plans to spin off most of its cable networks later in 2025. Finally, Sky, acquired in 2018, is a large television provider in the UK and Italy, and it also has a presence in Germany and Austria.

Share on Social Networks: